Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
This trial is active, not recruiting.
|Conditions||gastroesophageal reflux disease (gerd), non-erosive reflux disease (nerd)|
|Treatment||standard of care esophagogastroduodenoscopy (egd) with mucosal impedance testing|
|Start date||July 2013|
|End date||April 2016|
|Trial size||40 participants|
|Trial identifier||NCT02318862, 130084|
Gastroesophageal reflux disease (GERD) is a common condition affecting more than 100 million adults in the U.S., and it significantly impacts patients' quality of life while imposing billions of dollars of direct and indirect costs each year upon our healthcare system. Current diagnostic tests for GERD are highly invasive and medically inadequate, and the goal of this project is to develop a novel, minimally invasive Mucosal Impedance technique for more accurate detection of GERD while reducing costs.
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
Measurement of lower esophageal impedance using mucosal impedance catheter
time frame: During standard of care EGD
Male or female participants at least 18 years old.
- Patients undergoing standard of care EGD with 48-hr pH testing by BRAVO
- Previous diagnosis of reflux
- At least 18 years of age
- Those less than 18 years of age
- Unable to give informed consent
- Use of acid suppressive therapy within the last 10 days
- Known history of Barrett's esophagus, gastric surgery, alcoholism, or significant motility condition
|Official title||Assessment of Esophageal Epithelium Integrity With Mucosal Impedance|
|Principal investigator||Michael Vaezi, MD, PhD|
Call for more information